Will advance Boehringer Ingelheim's E. coli and Pichia pastoris expression platforms
Boehringer Ingelheim is widening the technological scope of its global technology collaboration with VTU Technology, a contract research and development company focused on protein expression based in Grambach/Graz, Austria.
The move follows the successful completion of the partners' first development programme, followed by an extension of the collaboration.
The agreement includes the advancement of Boehringer Ingelheim’s E. coli expression platform in addition to the competitive optimisation of Pichia pastoris platforms for the production of biopharmaceuticals.
'Widening our co-operation with VTU Technology increases our capabilities and resources for the development of microbial based biopharmaceutical processes. Adding E. coli based expression systems to the existing successful co-operation will strengthen our technology leadership and add significant potential for both companies,' said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim.
'This collaboration gives VTU certain access rights to Boehringer Ingelheim’s proprietary E. coli expression technologies broadening VTU’s range of services,' added Thomas Purkarthofer, Head of Business Development of VTU Technology.